Tarver In As FDA’s Device Center Director

Acting director Michelle Tarver has been named the new permanent director of the US FDA’s Center for Devices and Radiological Health.

CDRH director Michelle Tarver speaks at the 2024 Medtech Conference in Toronto, Ontario.
CDRH director Michelle Tarver speaks at the 2024 Medtech Conference in Toronto, Ontario. (Brian Bossetta/Citeline)

Michelle Tarver has been named the new permanent director of the device center at the US Food and Drug Administration, the agency confirmed Tuesday afternoon.

More from Medtech Insight

HHS Restructuring And Job Cuts Could Weaken FDA, Experts Say

 

About 3,500 full-time FDA employees are expected to be laid off as part of a restructuring of the Health and Human Services Department. Experts questioned whether the cuts could be implemented without harming FDA’s core mission.

LSI 2025: Vektor Medical CEO Says ‘Arrhythmia Is The Biggest Health Care Crisis Nobody Talks About,’ vMap Treats It With 91.1% Accuracy

 
• By 

Vektor Medical is ramping up efforts to bring its vMap technology used to identify arrhythmia sources to more US hospitals, start enrollment in a multinational trial, and commercialize in Europe, pending the CE mark. Medtech Insight sat down with CEO Rob Krummen at LSI 2025 to discuss their plans.

Get A Grip On Healthcare And Tariffs German Medtechs Tell Incoming Coalition

 
• By 

The IVD industry’s new 10-point plan for healthcare change shows that medtechs will keep calling the German government to account. Tariffs, sector resilience, digital functionality are among the pressing issues industry wants answers to.

THENA Capital ‘Makes History’ As UK’s First All-Female Early-Stage Medtech Fund

 

Only 16% of venture capital general partners in Europe are women, and only 9% of those have actual investment power. Thena Capital is aiming to "redefine the image of a venture capitalist."

More from United States

Research Finds Benefit From DME Suppliers For People Living With Diabetes

 
• By 

People living with diabetes who receive continuous glucose monitors (CGMs) through medical supply firms show higher compliance, lower costs of care, and fewer hospitalizations after one year than those who use pharmacies, a new study shows.

US FDA Should Regulate ‘Dangerous’ Prescription Software Platform As A Medical Device, Says Patient Advocacy Group

The Doctor Patient Forum says the US FDA should regulate a scoring platform from Bamboo Health intended to help clinicians calculate risk for opioid abuse as a medical device to ensure patient safety.

New CLIA Rule Updates Personnel Policies

 
• By 

A new set of clinical lab regulations, which came into effect in January, include higher fees, an expanded set of possible consequences for labs that are not in compliance, and revised employee standards.